23/02/2023

EuropaBio Response to Public Consultation on Horizon Europe – interim evaluation

EuropaBio provided input to the European Commission’s interim evaluation of Horizon Europe. The EU should continue to develop the various pillars of Horizon Europe to make full use of its scientific and industrial excellence and to help foster a stronger and more resilient research and innovation ecosystem for biotechnology across Europe.
17/02/2023

Inter-association letter to raise our concern about the proposed definition of “natural polymers” in the REACH restriction of microplastics

01/02/2023

Joint Statement: The Data Act is a leap into the unknown

28/11/2022

Enabling Patient Access to Transformational Therapeutic Innovations: Modernising the EU’s Cross-Border Healthcare Framework

European Industry trade and supply chain needs to respond to Covid-19 - Joint Letter to the EU Trade Ministers.
09/09/2022

The Essential Role of Enzymes | The unintended impact of the REACH revision on Enzymes – and consequences for EU Green Deal Objectives

08/09/2022

The role of enzymes as key enablers in the green transition and in enabling the European Commission’s sustainability ambitions in the EU Taxonomy and Sustainable Finance

29/07/2022

Towards an accurate accounting for carbon from biomass in the Product Environmental Footprint (PEF)

31/05/2021

EuropaBio Key Messages to 94th Pharmaceutical Committee – 28 May 2021

26/05/2021

Inter-association letter to the EU Ministers of Agriculture and DG SANTE

12/02/2021

EuropaBio Response to Public Consultation on the Evaluation of Patient Rights in Cross-Border Healthcare

EuropaBio sees the Directive on cross-border healthcare as an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases.
20/01/2021

Revision of the EU legislation on medicines for children and rare diseases

Read our submission to the European Commission’s Inception Impact Assessment titled “Revision of the EU legislation on medicines for children and rare diseases“.
24/12/2020

Joint Statement: Comitology Reform Threatens Innovation

30/11/2020

Call for more effective EU regulation of Clinical Trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms

Call for more effective EU regulation of clinical trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms
20/10/2020

EuropaBio on Use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making

EuropaBio Position Paper on the use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making.
19/10/2020

Application of the ATMP Hospital Exemption in the EU

EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
30/09/2020

EuropaBio Patient engagement with the European Medicines Agency

EuropaBio Patient engagement with the European Medicines Agency
13/08/2020

Statement in response to the publication of the European Commission’s evaluation of the Orphan and Paediatric Regulations

Read our Statement in response to the publication of the European Commission’s evaluation of the Orphan and Paediatric Regulations.
03/08/2020

Joint Statement on the Health Innovation Partnership Proposal

Health industry sectors, representing pharmaceutical and medical technology companies welcome the publication of the Partnership Proposal as a significant milestone towards a European Partnership for Health Innovation.
30/07/2020

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation.
30/07/2020

EuropaBio response to the public consultation on the Roadmap for an EU Pharmaceutical Strategy

EuropaBio response to the public consultation on the Roadmap for an EU Pharmaceutical Strategy.